Last updated on October 2018

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available.


Brief description of study

The purpose of this open-label, single arm, multi-center Expanded Treatment Protocol (ETP) is to provide early access to ruxolitinib and evaluate safety information in patients with PV, who are HU resistant or intolerant and who have no other standard treatment option, nor do they qualify for another clinical study for PV.

Clinical Study Identifier: NCT02292446

Contact Investigators or Research Sites near you

Start Over

Novartis Pharmaceuticals

Novartis Investigative Site
A-1090 Vienna, Austria

Novartis Pharmaceuticals

Novartis Investigative Site
Linz, Austria

Novartis Pharmaceuticals

Novartis Investigative Site
Rankweil, Austria

Novartis Pharmaceuticals

Novartis Investigative Site
Salzburg, Austria

Novartis Pharmaceuticals

Novartis Investigative Site
Wels, Austria

Novartis Pharmaceuticals

Novartis Investigative Site
Antwerp, Belgium

Novartis Pharmaceuticals

Novartis Investigative Site
Brugge, Belgium

Novartis Pharmaceuticals

Novartis Investigative Site
Bruxelles, Belgium

Novartis Pharmaceuticals

Novartis Investigative Site
Leuven, Belgium

Novartis Pharmaceuticals

Novartis Investigative Site
Liege, Belgium

Novartis Pharmaceuticals

Novartis Investigative Site
Yvoir, Belgium

Novartis Pharmaceuticals

Novartis Investigative Site
Pleven, Bulgaria

Novartis Pharmaceuticals

Novartis Investigative Site
Plovdiv, Bulgaria

Novartis Pharmaceuticals

Novartis Investigative Site
Sofia, Bulgaria

Novartis Pharmaceuticals

Novartis Investigative Site
Vancouver, BC Canada

Novartis Pharmaceuticals

Novartis Investigative Site
Hamilton, ON Canada

Novartis Pharmaceuticals

Novartis Investigative Site
Santiago, Chile

Novartis Pharmaceuticals

Novartis Investigative Site
Bayonne, France

Novartis Pharmaceuticals

Novartis Investigative Site
Angers Cedex 1, France

Novartis Pharmaceuticals

Novartis Investigative Site
Avignon cedex 9, France

Novartis Pharmaceuticals

Novartis Investigative Site
Bordeaux, France

Novartis Pharmaceuticals

Novartis Investigative Site
Dunkerque, France

Novartis Pharmaceuticals

Novartis Investigative Site
Le Mans Cedex 09, France

Novartis Pharmaceuticals

Novartis Investigative Site
Marseille, France

Novartis Pharmaceuticals

Novartis Investigative Site
Meaux cedex, France

Novartis Pharmaceuticals

Novartis Investigative Site
Metz, France

Novartis Pharmaceuticals

Novartis Investigative Site
Mulhouse cedex, France

Novartis Pharmaceuticals

Novartis Investigative Site
Nice Cedex, France

Novartis Pharmaceuticals

Novartis Investigative Site
Paris, France

Novartis Pharmaceuticals

Novartis Investigative Site
Perpignan, France

Novartis Pharmaceuticals

Novartis Investigative Site
Pierre-Benite Cedex, France

Novartis Pharmaceuticals

Novartis Investigative Site
Pringy cedex, France

Novartis Pharmaceuticals

Novartis Investigative Site
Toulouse Cedex 9, France

Novartis Pharmaceuticals

Novartis Investigative Site
Vandoeuvre Les Nancy, France

Novartis Pharmaceuticals

Novartis Investigative Site
Villejuif Cedex, France

Novartis Pharmaceuticals

Novartis Investigative Site
Mannheim, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Aschaffenburg, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Augsburg, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Bad Soden, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Berlin, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Bottrop, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Eisenach, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Erlangen, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Frankfurt, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Friedrichshafen, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Hamburg, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Hamm, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Heidelberg, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Heilbronn, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Koblenz, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Mutlangen, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Stuttgart, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Ulm, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Wuerzburg, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Monterrey, Mexico

Novartis Pharmaceuticals

Novartis Investigative Site
Fredrikstad, Norway

Novartis Pharmaceuticals

Novartis Investigative Site
Tromso, Norway

Novartis Pharmaceuticals

Novartis Investigative Site
Braga, Portugal

Novartis Pharmaceuticals

Novartis Investigative Site
Coimbra, Portugal

Novartis Pharmaceuticals

Novartis Investigative Site
Lisboa, Portugal

Novartis Pharmaceuticals

Novartis Investigative Site
Singapore, Singapore

Novartis Pharmaceuticals

Novartis Investigative Site
Lulea, Sweden

Novartis Pharmaceuticals

Novartis Investigative Site
Uddevalla, Sweden

Novartis Pharmaceuticals

Novartis Investigative Site
Khon Kaen, Thailand

Novartis Pharmaceuticals

Novartis Investigative Site
Bangkok, Thailand

Novartis Pharmaceuticals

Novartis Investigative Site
Chiang Mai, Thailand

Novartis Pharmaceuticals

Novartis Investigative Site
Viña del Mar, Chile

Novartis Pharmaceuticals

Novartis Investigative Site
Chambéry Cedex, France

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.